Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK1/2 and p38 pathways

International Journal of Ophthalmology

Volumn 4, Issue 2, 2011, Pages 150-155

  Zhong, Yan Yan ^a   Zhang, Hai Feng ^a   Zhong, Jia Xi ^b   Bai, Lang ^c   Lu, Xiao He ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cornea; Dihy droartem isinin; Extracellular regulated kinases 1 2; Neov ascularization; P38

Indexed keywords

EID: 84875725393     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2011.02.08     Document Type: Article

References (24)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Riazi-Esfahani M, Peyman GA, Aydin E, Kazi AA, Kivilcim M, Sanders DR . Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea. 2006;25:801-805.
3. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin) Br J Ophthalmol. 2007;91:804-807.
4. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
5. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin) Cornea. 2008;27:349-352.
6. Tille JC, Wang X, Lipson KE, McMahon G, Ferrara N, Zhu Z, Hicklin DJ, Sleeman JP, Eriksson U, Alitalo K, Pepper MS. Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. Exp Cell Res. 2003;285:286-298.
7. Anderson SM, Chen TT, Iruela-Arispe ML, Sequra T. Th e phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF. Biomaterials. 2009;30:4618- 4628.
8. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin Y G, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009;124:1045-1053.
9. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911-1912.
10. Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C, Fotsis T. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res. 2004;64:7936-7946.
11. Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest. 2009;89:38-46.
12. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568-581.
13. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Hu ot J. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem. 2000;275:10661-10672.
14. Klayman DL. Qinghaosu (Artemisinin)-an antimalarial drug from CHINA. Science. 1985;228:1049-1055.
15. Taylor WR, White N J. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25-61.
16. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res. 2003;48:231-236.
17. Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol. 2004;53:423-432.
18. Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P, Lansen J, Mazué G, Gomes M, Taylor WR, Olliaro P. Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol. 2006;21:83-93.
19. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
20. Jiang A, Li C, Gao Y, Zhang M, Hu J, Kuang W, Hao S, Yang W, Xu C, Gao G, Wang Z, Liu Z. In vivo and in vitro inhibitory effect of amniotic extraction on neovascularization. Cornea. 2006;25:36-40.
21. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost. 2000;26:561-569.
22. Kang S, Chung SK. The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits. Cornea. 2010;29:192-196.
23. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22:201-207.
24. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996;7:259-270.